John P. O’Donnell

3.6k citations

51 papers · 2.4k indexed · 1 hit paper · h-index 20

Impact in

Molecular Medicine top 0.5%
- Antibiotic Resistance in Bacteria
Applied Microbiology and Biotechnology top 0.5%
- Antibiotic Use and Resistance

Papers in

Molecular Medicine 22
- Antibiotic Resistance in Bacteria 22
Pharmacology 23
- Antibiotics Pharmacokinetics and Efficacy 20
- Pharmacogenetics and Drug Metabolism 4

Co-authors: R. Scott Obach Deepak Dalvie Amit S. Kalgutkar S. Cyrus Khojasteh-Bakht Alita A. Miller David P. Westfall Jeffrey S. Fedan G. Kurt Hogaboom
Journals: Antimicrobial Agents and Chemotherapy (10 papers)Open Forum Infectious Diseases (5 papers)Drug Metabolism and Disposition (4 papers)Journal of Pharmaceutical Sciences (3 papers)European Journal of Pharmacology (3 papers)
Partner nations: United States United Kingdom Belarus

In The Last Decade

John P. O’Donnell

50 papers receiving 2.3k citations

Hit Papers

align trajectories log scale

Efficacy and safety of sulbactam–durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii–calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK) 2023 · 146 citations

Peers

Countries citing papers authored by John P. O’Donnell

Since Specialization

Citations

This map shows the geographic impact of John P. O’Donnell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John P. O’Donnell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John P. O’Donnell more than expected).

Fields of papers citing papers by John P. O’Donnell

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John P. O’Donnell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John P. O’Donnell. The network helps show where John P. O’Donnell may publish in the future.

Co-authors

The 25 scholars most cited alongside John P. O’Donnell, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with John P. O’Donnell Line = papers co-authored together John P. O’Donnell links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	P-1251. Pharmacometric Analyses to Support Dose Selection of Zoliflodacin, a First-in-Class Oral Antibiotic Being Developed for the Treatment of Uncomplicated Gonorrhea Open Forum Infectious Diseases ·Sujata M. Bhavnani, Sumayyah Harakat, Jeffrey Hammel, Alison Luckey, Wendell Gordon, Kajal Larson, John P. O’Donnell, Christopher M. Rubino	2025	0
2	Sulbactam–durlobactam: a β-lactam/β-lactamase inhibitor combination targeting Acinetobacter baumannii Future Microbiology ·Sarah M. McLeod, John P. O’Donnell, Navaneeth Narayanan, John Mills, Keith S. Kaye	2024	15
3	The Pharmacokinetics/Pharmacodynamic Relationship of Durlobactam in Combination With Sulbactam in In Vitro and In Vivo Infection Model Systems Versus Acinetobacter baumannii-calcoaceticus Complex Clinical Infectious Diseases ·John P. O’Donnell, Sujata M. Bhavnani	2023	24
4	2549. Pharmacometric Analyses to Support Sulbactam-Durlobactam (SUL-DUR) Dosing Regimens in Patients with Altered Renal Function Open Forum Infectious Diseases ·Kajal Larson, Sujata M. Bhavnani, Jeffrey Hammel, Sumayyah Harakat, John P. O’Donnell, Christopher M. Rubino	2023	1
5	Efficacy and safety of sulbactam–durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii–calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK) The Lancet Infectious Diseases ·Keith S. Kaye, Andrew F. Shorr, Richard G. Wunderink, Bin Du, XU Yan-ka, Khurram Rana, Alita A. Miller, Drew Lewis, John P. O’Donnell, Lan Chen, Harald H. Reinhart, Subasree Srinivasan, Robin Isaacs, David Altarac Hit paper breakdown →	2023	146
6	Zoliflodacin: An Oral Spiropyrimidinetrione Antibiotic for the Treatment of Neisseria gonorrheae, Including Multi-Drug-Resistant Isolates ACS Infectious Diseases ·Patricia A. Bradford, Alita A. Miller, John P. O’Donnell, John P. Mueller	2020	98
7	Pharmacokinetic/pharmacodynamic considerations for new and current therapeutic drugs for uncomplicated gonorrhoea—challenges and opportunities Clinical Microbiology and Infection ·Ursula Theuretzbacher, Lindley A. Barbee, Kristie L. Connolly, George L. Drusano, Tarthang Tulku, Edward W. Hook, Ann E. Jerse, John P. O’Donnell, Magnus Unemo, Françoise Van Bambeke, Brian VanScoy, Peter Warn, Brian J. Werth, F. Franceschi, Emilie Alirol	2020	15
8	N-Hydroxyformamide LpxC inhibitors, their in vivo efficacy in a mouse Escherichia coli infection model, and their safety in a rat hemodynamic assay Bioorganic & Medicinal Chemistry ·Hideshige Hara, Adam B. Shapiro, Janelle Comita-Prevoir, W. Duncan Robertson, Jing Zhang, Seth Ribe, April Chen, 隆葛原, Samir H. Moussa, Nicole Carter, Mark Sylvester, Jan Antoinette C. Romero, 王增发, M. Sacco, Yu Chen, John P. O’Donnell, Thomas F. Durand-Réville, Alita A. Miller, Rubén Tommasi	2020	16
9	Safety and Pharmacokinetics (PK) in Humans of Intravenous ETX2514, a β-lactamase Inhibitor (BLI) which Broadly Inhibits Ambler Class A, C, and D β-lactamases Open Forum Infectious Diseases ·Jason D. Lickliter, Kenneth Lawrence, John P. O’Donnell, Robin Isaacs	2017	8
10	Pharmacokinetics/pharmacodynamics of a β-lactam and β-lactamase inhibitor combination: a novel approach for aztreonam/avibactam Journal of Antimicrobial Chemotherapy ·Renu Singh, Aryun Kim, MELİH ATAHAN GÜVEN, Jennifer J. Harris, Robert E. McLaughlin, 立石容子, John P. O’Donnell, Patricia A. Bradford, Ann E. Eakin	2015	75
11	Clinically Relevant Gram-Negative Resistance Mechanisms Have No Effect on the Efficacy of MC-1, a Novel Siderophore-Conjugated Monocarbam Antimicrobial Agents and Chemotherapy ·Craig J. McPherson, Lisa Aschenbrenner, Brian M. Lacey, Kelly Fahnoe, M. Megan Lemmon, Steven M. Finegan, H. Emmons, John P. O’Donnell, John P. Mueller, Andrew P. Tomaras	2012	73
12	Effect of Linezolid on the 50% Lethal Dose and 50% Protective Dose in Treatment of Infections by Gram-Negative Pathogens in Naive and Immunosuppressed Mice and on the Efficacy of Ciprofloxacin in an Acute Murine Model of Septicemia Antimicrobial Agents and Chemotherapy ·Andrea Marra, Lucinda Lamb, Ivette Medina, D. M. George, Glenn Gibson, Joel R. Hardink, Antony C. Leberatto, F Sanz, John P. O’Donnell	2012	11
13	Differentiation of Arrhythmia Risk of the Antibacterials Moxifloxacin, Erythromycin, and Telithromycin Based on Analysis of Monophasic Action Potential Duration Alternans and Cardiac Instability Journal of Pharmacology and Experimental Therapeutics ·Todd Wisialowski, Kimberly Crimin, Susana Albelda, John P. O’Donnell, Bernard Fermini, Anthony A. Fossa	2006	34
14	A Comprehensive Listing of Bioactivation Pathways of Organic Functional Groups Current Drug Metabolism ·Amit S. Kalgutkar, Iain Gardner, R. Scott Obach, Christopher L. Shaffer, Ernesto Callegari, Kirk R. Henne, Abdul Mutlib, Deepak Dalvie, Jose Antonio Arranz-Amo, Yasuhiro Nakai, John P. O’Donnell, Jason Boer, Shawn Harriman	2005	435
15	METABOLISM, PHARMACOKINETICS, TISSUE DISTRIBUTION, AND EXCRETION OF [14C]CP-424391 IN RATS Drug Metabolism and Disposition ·S. Cyrus Khojasteh-Bakht, John P. O’Donnell, Hassan G. Fouda, Michael J. Potchoiba	2004	9
16	The effect of feed conditions in the emulsion catalytic chain transfer polymerization of alkyl methacrylates Journal of Polymer Science Part A Polymer Chemistry ·David M. Haddleton, Rosniwati Ghafar, John P. O’Donnell, Stuart N. Richards	1999	1
17	Relationship between covalent binding to microsomal protein and the destruction of adrenal cytochrome P-450 by spironolactone Toxicology ·Howard D. Colby, John P. O’Donnell, 党盼峰, Bárbara de Andrade Sant'Anna, Maciej Karwat, Elisa Göckeritz	1991	4
18	A study of the atropine-resistant component of the neurogenic response of the rabbit urinary bladder European Journal of Pharmacology ·Penelope A. Longhurst, John A. Belis, John P. O’Donnell, Su Bin Kwon, David P. Westfall	1984	36
19	Specific, irreversible antagonism of histamine receptors in the isolated guinea-pig vas deferens by 4(5)-[5-(4-azido-2-nitroanilino)ethyl] imidazole, a photoaffinity analog of histamine European Journal of Pharmacology ·John P. O’Donnell, G. Kurt Hogaboom, Jeffrey S. Fedan	1981	14
20	Heteroaromatic fused-ring mesoionic compounds. Sydno[3,4-a]quinoxalines The Journal of Organic Chemistry ·Robert A. Coburn, John P. O’Donnell	1972	13

About John P. O’Donnell

John P. O’Donnell is a scholar working on Molecular Medicine, Pharmacology, Applied Microbiology and Biotechnology, Microbiology and Pharmacology, having authored 51 papers that have together received 2.4k indexed citations. Recurring topics across this work include Antibiotic Resistance in Bacteria (22 papers), Antibiotics Pharmacokinetics and Efficacy (20 papers), Pneumonia and Respiratory Infections (8 papers), Reproductive tract infections research (4 papers), Pharmacogenetics and Drug Metabolism (4 papers), Synthesis and Biological Evaluation (4 papers), Advanced Polymer Synthesis and Characterization (4 papers) and Neuropeptides and Animal Physiology (3 papers). The work is most often cited by research in Molecular Medicine (701 citations), Applied Microbiology and Biotechnology (214 citations), Pharmacology (357 citations), Pharmacology (588 citations) and Physiology (121 citations). John P. O’Donnell has collaborated with scholars based in United States, United Kingdom and Belarus. Frequent co-authors include R. Scott Obach, Deepak Dalvie, Amit S. Kalgutkar, S. Cyrus Khojasteh-Bakht, Alita A. Miller, David P. Westfall, Jeffrey S. Fedan, G. Kurt Hogaboom, Robin Isaacs and John P. Mueller. Their work appears in journals such as Antimicrobial Agents and Chemotherapy, Open Forum Infectious Diseases, Drug Metabolism and Disposition, Journal of Pharmaceutical Sciences and European Journal of Pharmacology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact